Genomatica Establishes Expanded Multi-Year Collaboration With DSM to Develop Improved Bio-Based Processes
This partnership centers round the general implementation of Genomatica's proprietary metabolic modeling and simulation technologies, capabilities, and expertise to help DSM develop improved biological processes.
28/06/06 Genomatica, Inc., a leading systems biology company addressing metabolism-driven product opportunities, announced today it has entered into an expanded multi-year collaboration and license agreement with DSM, a global supplier of ingredients based on fermentation and enzyme technology to the chemical, pharmaceutical and food industries. This partnership centers round the general implementation of Genomatica's proprietary metabolic modeling and simulation technologies, capabilities, and expertise to help DSM develop improved biological processes to produce valuable products of interest to DSM. This partnership builds on a previous collaboration between the two companies where Genomatica successfully established the utility of its technology to improve the effectiveness of certain DSM research and development programs.
"We are excited to be expanding our relationship with DSM, one of the largest chemical and biotechnology companies in Europe," commented Christophe H. Schilling, Ph.D., President and Chief Scientific Officer at Genomatica. "Our research efforts and accomplishments are demonstrating increasing positive impacts for DSM. We believe this momentum will continue as we advance our technology platforms and build toward providing more fully integrated metabolic engineering solutions to DSM and our customers worldwide for developing next generation microbial bio-factories to produce valuable industrial products from sustainable feedstocks."
"Genomatica offers an ideal combination of State-of-the-art technology and a very professional project management. Their technology package will certainly have a big impact on the continuous need to further improve the performance of our cell-factory based processes," commented Marco van den Berg, Principal Scientist at DSM.
Financial details of the agreement were not disclosed, but include research and development support, technology license fees, and milestone payments.
